Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Jan 23

PMID 38256945

Authors

Sung Jin Kim

Myungchan Park

Ahnryul Choi

Sangjun Yoo

Affiliations

Soon will be listed here.

Abstract

This review systematically addresses the correlation between the microbiome and prostate cancer and explores its diagnostic and therapeutic implications. Recent research has indicated an association between the urinary and gut microbiome composition and prostate cancer incidence and progression. Specifically, the urinary microbiome is a potential non-invasive biomarker for early detection and risk evaluation, with altered microbial profiles in prostate cancer patients. This represents an advancement in non-invasive diagnostic approaches to prostate cancer. The role of the gut microbiome in the efficacy of various cancer therapies has recently gained attention. Gut microbiota variations can affect the metabolism and effectiveness of standard treatment modalities, including chemotherapy, immunotherapy, and hormone therapy. This review explores the potential of gut microbiome modification through dietary interventions, prebiotics, probiotics, and fecal microbiota transplantation for improving the treatment response and mitigating adverse effects. Moreover, this review discusses the potential of microbiome profiling for patient stratification and personalized treatment strategies. While the current research identifies the pivotal role of the microbiome in prostate cancer, it also highlights the necessity for further investigations to fully understand these complex interactions and their practical applications in improving patient outcomes in prostate cancer management.

Citing Articles

NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.

Fanijavadi S, Hansen T, Zedan A Biomolecules. 2025; 15(2).

PMID: 40001576 PMC: 11852595. DOI: 10.3390/biom15020273.

Exploring the Link Between Obligate Anaerobe-Related Dysbiosis and Prostate Cancer Development: A Pilot Study.

Ladoukakis E, Oliver T, Wilks M, Lane E, Chinegwundoh F, Shaw G Cancers (Basel). 2025; 17(1.

PMID: 39796699 PMC: 11720123. DOI: 10.3390/cancers17010070.

Serum Calcium Level at Diagnosis Can Predict Lethal Prostate Cancer Relapse.

Fekete Z, Ignat P, Jakab H, Todor N, Laszlo I, Muntean A J Clin Med. 2024; 13(16).

PMID: 39200986 PMC: 11355581. DOI: 10.3390/jcm13164845.

References

Sfanos K, Sauvageot J, Fedor H, Dick J, De Marzo A, Isaacs W . A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate. 2008; 68(3):306-20. DOI: 10.1002/pros.20680. View

Ly L, Rowles 3rd J, Muller Paul H, Alves J, Yemm C, Wolf P . Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells. J Steroid Biochem Mol Biol. 2019; 199:105567. PMC: 7333170. DOI: 10.1016/j.jsbmb.2019.105567. View

Alanee S, El-Zawahry A, Dynda D, McVary K, Karr M, Braundmeier-Fleming A . Prospective examination of the changes in the urinary microbiome induced by transrectal biopsy of the prostate using 16S rRNA gene analysis. Prostate Cancer Prostatic Dis. 2019; 22(3):446-452. DOI: 10.1038/s41391-018-0120-3. View

Eftekhari A, Dizaj S, Chodari L, Sunar S, Hasanzadeh A, Ahmadian E . The promising future of nano-antioxidant therapy against environmental pollutants induced-toxicities. Biomed Pharmacother. 2018; 103:1018-1027. DOI: 10.1016/j.biopha.2018.04.126. View

Yu S, Jung S . The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms. Diagnostics (Basel). 2022; 12(8). PMC: 9406308. DOI: 10.3390/diagnostics12081862. View

Wang Y, Jacobs E, Newton C, McCullough M . Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Int J Cancer. 2016; 138(12):2846-55. DOI: 10.1002/ijc.30027. View

Lu Y, Liu Z, Li Y, Xu H, Fang W, He F . Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo. Int J Nanomedicine. 2022; 17():1593-1608. PMC: 8994610. DOI: 10.2147/IJN.S357462. View

Seibert T, Fan C, Wang Y, Zuber V, Karunamuni R, Parsons J . Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018; 360:j5757. PMC: 5759091. DOI: 10.1136/bmj.j5757. View

Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M . A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate. 2018; 79(1):81-87. DOI: 10.1002/pros.23713. View

10.

Porter C, Shrestha E, Peiffer L, Sfanos K . The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018; 21(3):345-354. DOI: 10.1038/s41391-018-0041-1. View

11.

Atashafrooz F, Rokhbakhsh-Zamin F . Frequency and Type Distribution of Human Papilloma Virus in Patients with Prostate Cancer, Kerman, Southeast of Iran. Asian Pac J Cancer Prev. 2016; 17(8):3953-8. View

12.

Zhong W, Wu K, Long Z, Zhou X, Zhong C, Wang S . Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 2022; 10(1):94. PMC: 9202177. DOI: 10.1186/s40168-022-01289-w. View

13.

Medel-Flores O, Valenzuela-Rodriguez V, Ocadiz-Delgado R, Castro-Munoz L, Hernandez-Leyva S, Lara-Hernandez G . Association between HPV infection and prostate cancer in a Mexican population. Genet Mol Biol. 2018; 41(4):781-789. PMC: 6415601. DOI: 10.1590/1678-4685-GMB-2017-0331. View

14.

Breinbjerg A, Mohamed L, Nielsen S, Rittig S, Tullus K, Kamperis K . Pitfalls in Diagnosing Urinary Tract Infection in Children below the Age of 2: Suprapubic Aspiration vs Clean-Catch Urine Sampling. J Urol. 2021; 206(6):1482-1489. DOI: 10.1097/JU.0000000000002117. View

15.

Levy M, Kolodziejczyk A, Thaiss C, Elinav E . Dysbiosis and the immune system. Nat Rev Immunol. 2017; 17(4):219-232. DOI: 10.1038/nri.2017.7. View

16.

Kustrimovic N, Bombelli R, Baci D, Mortara L . Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment. Int J Mol Sci. 2023; 24(2). PMC: 9860633. DOI: 10.3390/ijms24021511. View

17.

Jain S, Suklabaidya S, Das B, Raghav S, Batra S, Senapati S . TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. Prostate. 2015; 75(10):1020-33. DOI: 10.1002/pros.22983. View

18.

Aragon I, Herrera-Imbroda B, Queipo-Ortuno M, Castillo E, Del Moral J, Gomez-Millan J . The Urinary Tract Microbiome in Health and Disease. Eur Urol Focus. 2017; 4(1):128-138. DOI: 10.1016/j.euf.2016.11.001. View

19.

Guri A, Hurvitz Florenthal M, Scheier E, Mahlab-Guri K, Balla U . Contamination rates of different methods of urine culture collection in children: A retrospective cohort study. J Paediatr Child Health. 2021; 57(8):1281-1287. DOI: 10.1111/jpc.15457. View

20.

Wolfe A, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald M . Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol. 2012; 50(4):1376-83. PMC: 3318548. DOI: 10.1128/JCM.05852-11. View